Press Releases

GW Welcomes Move by UK Regulator to Provide More Information for Sativex Prescribers

13 December 2007

GW Pharmaceuticals plc (AIM: GWP) welcomes the publication today by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) of a Public Information Report on Sativex, GW’s can... more

GW Commences Sativex® Phase III Clinical Trial in MS Spasticity

3 December 2007

GW Pharmaceuticals plc (AIM: GWP) today announces that it has started a new Phase III trial of Sativex® in Multiple Sclerosis (MS) Spasticity. This trial is designed to resolve the outstanding issue a... more

Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain

26 November 2007

GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announced that the first US Phase II/III dose-ranging trial has been initiated to evaluate the efficacy and safety of Sative... more

New Published Study Shows Sativex® Successfully Treats Neuropathic Pain

12 November 2007

GW Pharmaceuticals plc (AIM: GWP) today announces that The International Association of the Study of Pain has published online the results of a study in its official journal Pain, showing that Sativex... more

Positive Sativex® Study Confirms Long Term Efficacy in MS Neuropathic Pain

22 October 2007

GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled “randomized withdrawal” study of Sativex® in patients with neuropathic pain due to Multiple Sclerosis (MS).... more

Sativex® receives Qualifying Notice for approval in Canada for the relief of Cancer Pain

22 October 2007

GW Pharmaceuticals plc (AIM: GWP) and Bayer HealthCare Pharmaceuticals announce that Health Canada, the Canadian regulatory agency, has issued a Qualifying Notice for the approval of Sativex® in the r... more

New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain

17 October 2007

GW Pharmaceuticals plc (AIM: GWP) today announces that the Journal of Clinical Therapeutics has published the results of a study which show that Sativex® provides effective long term treatment of cent... more

Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment

30 August 2007

GW Pharmaceuticals plc (AIM: GWP) announces that patient recruitment is now complete in its pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain.... more

Health Canada Approves Sativex® For Cancer Pain

7 August 2007

GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, today announce that Health Canada has approved Sativex®, a cannabis derived pharmaceutical treatment, as adjunctive analgesi... more

GW and Otsuka Enter Into Global Cannabinoid Research Collaboration

9 July 2007

GW Pharmaceuticals plc and Otsuka Pharmaceutical Co., Ltd today announce a major long term strategic cannabis alliance. An exclusive licence and development agreement has been signed for Sativex® in t... more

Interim Results For The Six Months Ended 31 March 2007

19 June 2007

GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2007. ... more

GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders

4 June 2007

GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders... more

GW and Otsuka Receive Hart-Scott-Rodino Clearance for Sativex® US License Agreement

22 March 2007

GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co. Ltd today announce that they have each received early termination by the United States Federal Trade Commission and the Antitrust Divisi... more

GW Pharmaceuticals plc announces changes to Board of Directors

15 March 2007

GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Mr Richard Forrest as a non-executive director. Mr Forrest replaces Mr David Morrison who is standing down from the Board with effe... more

Phase III Sativex® Data Published in Leading Neurology Journal

28 February 2007

GW Pharmaceuticals plc (AIM: GWP) a leading neurology journal, The European Journal of Neurology, today reports a study showing that Sativex significantly reduces intractable spasticity (spasms and st... more

GW and Otsuka Announce Major Long Term Strategic Cannabinoid Alliance

14 February 2007

GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance.... more

Preliminary Results for the Year Ended 30 September 2006

30 January 2007

Porton Down, UK, 30 January 2007: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for t... more

GW strengthens board with appointment of James Noble

26 January 2007

Porton Down, UK, 26 January 2007: GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment of James Noble as an independent non-executive director with immediate effect. James has also... more

Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients

15 January 2007

GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain. These studies are part of a prog... more